Search results for "colorectal"

showing 10 items of 1167 documents

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

An international assessment of the adoption of enhanced recovery after surgery (ERAS®) principles across colorectal units in 2019–2020

2021

Aim The Enhanced Recovery After Surgery (ERAS® ) Society guidelines aim to standardise perioperative care in colorectal surgery via 25 principles. We aimed to assess the variation in uptake of these principles across an international network of colorectal units. Method An online survey was circulated amongst European Society of Coloproctology members in 2019/20. For each ERAS® principle, respondents were asked to score how frequently the principle was implemented in their hospital, from 1 ('rarely') to 4 ('always'). Respondents were also asked to recall whether practice had changed since 2017. Subgroup analyses based on hospital characteristics were conducted. Results Of hospitals approache…

medicine.medical_specialtyPrehabilitationmedicine.medical_treatmentMEDLINEColorectal NeoplasmPerioperative CareNOmedicineHumans03.02. Klinikai orvostanPerioperative OptimisationEnhanced recovery after surgeryDigestive System Surgical ProceduresLS7_4Enhanced Recovery After Surgery (ERAS)business.industryGastroenterologyDigestive System Surgical ProcedureGuidelineColorectal surgeryEnhanced Recovery After Surgery (ERAS); Perioperative Optimisation; SurgeryFamily medicinePerioperative careNasogastric intubationSurgeryPreoperative fastingColorectal NeoplasmsEnhanced Recovery After SurgerybusinessColorectal SurgeryHumanColorectal Disease
researchProduct

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative

2014

Colorectal cancer is one of the most common cancers in Europe. Over the past few decades, important advances have been made in screening, staging and treatment of colorectal cancer. However, considerable variation between and within European countries remains, which implies that further improvements are possible. The most important remaining question now is: when are we, health care professionals, delivering the best available care to patients with colon or rectal cancer? Currently, quality assurance is a major issue in colorectal cancer care and quality assurance awareness is developing in almost all disciplines involved in the treatment of colorectal cancer patients. Quality assurance has…

medicine.medical_specialtyQuality managementQuality Assurance Health CareColorectal cancercolorectal cancerauditAuditquality assurancemultidisciplinarityFeedbackHealth caremedicineHumansguidelinesIntensive care medicineQuality of Health CareSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAClinical Trials as TopicClinical Auditbusiness.industryCancerHematologyGuidelinemedicine.diseaseSurgeryEuropeClinical trialOncologyData Interpretation StatisticalPractice Guidelines as TopicColorectal NeoplasmsbusinessQuality assurance
researchProduct

Non-Surgical Treatment of Localized Rectal Cancer Is an Experimental Option

2016

medicine.medical_specialtyRectal Neoplasmsbusiness.industryColorectal cancerGeneral EngineeringCancer030230 surgeryConservative Treatmentmedicine.diseaseSurgery03 medical and health sciencesTreatment Outcome0302 clinical medicine030220 oncology & carcinogenesisHumansMedicineSurgical treatmentbusinessCirugía Española (English Edition)
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Histological effects of He-Ne laser on the healing of experimental colon anastomoses in the rat

1990

Despite technical advances, the incidence of anastomotic leaks in elective colorectal surgery remains around 14%, Recent studies suggest that the use of low energy lasers may enhance wound healing in different tissues in a selective, nondestructive manner. Based on these findings we have attempted to provide experimental background on the histological effects of He-Ne laser during the early stages of healing in 70 colonic anastornoses performed on rats, The irradiation of the anastomoses by two doses of 3.6 J/cm produces an increase in the populations of round cells and fibroblasts of the scar tissue, an increase in new vessel formation and a significant improvement in epithelialization. Th…

medicine.medical_specialtyRound cellsPathologyMaterials scienceLow energyAnastomotic leaksScar tissuemedicineHe ne laserAnastomosisWound healingColorectal surgerySPIE Proceedings
researchProduct

Screening for colorectal cancer with immunochemical faecal occult blood tests.

2012

Population-based studies have shown that guaiac faecal occult blood testing followed by colonoscopy in case of positivity can reduce colorectal cancer mortality. However these tests have been criticised for their fairly low sensitivity. For this reason attention has been given to alternative tests. The aim of this paper is to review the evidence for screening for colorectal cancer using qualitative immunochemical faecal occult blood tests. For the complete range of tested cut-off values, immunochemical faecal occult blood tests lead to higher diagnostic yield, improved sensitivity and greater participation. The optimal number of samples and the optimal cut-off value has to suit local resour…

medicine.medical_specialtyScreening testColorectal cancerCost-Benefit AnalysisPopulationColonoscopyGastroenterologySensitivity and SpecificityChromatography AffinityJapanInternal medicinemedicineHumansMass ScreeningSampling (medicine)educationMass screeningEarly Detection of Cancereducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyFaecal occult bloodPatient Acceptance of Health Caremedicine.diseaseEuropeOccult BloodNorth AmericaIndicators and ReagentsFaecal occult blood testbusinessColorectal NeoplasmsGuaiacDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct

Milestones in robotic colorectal surgery development: an historical overview

2020

The present article is a historical review intended to trace the most important phases in the development of robotic surgical technology, with a special focus on colorectal surgery. The initial section considers the origin and some etymological aspects of the word “robot”. Then, a historical overview traces the development of robotic technology in industry and its implementation within the operating theatres. Finally, the first publications concerning robot-assisted colon and rectal surgery are reported together with a brief state of the art about this issue.

medicine.medical_specialtySettore MED/18 - Chirurgia Generalebusiness.industryGeneral surgerymedicineRobotic surgeryRobotic surgery colorectal surgery historybusinessColorectal surgery
researchProduct

Validation of two short questionnaires assessing physical activity in colorectal cancer patients

2018

Background In order to investigate the impact of adherence to recommendations of physical activity and sedentary time on health outcomes in clinical trials, there is a need for feasible tools such as questionnaires that can give representative estimates of these measures. The primary aim of the present study was to validate two such questionnaires and their ability to estimate adherence to the recommendations of physical activity defined as moderate-to- vigorous physical activity or moderate physical activity of at least 150 min/week in colorectal cancer patients. Secondarily, self-reported sedentary time from the HUNT-PAQ was also evaluated. Methods Participants from 'The Norwegian dietary…

medicine.medical_specialtySports medicineColorectal cancerPhysical activityPhysical activity recommendationsPhysical Therapy Sports Therapy and RehabilitationHealth outcomes03 medical and health sciences0302 clinical medicineSenseWear armband minimedicineOrthopedics and Sports Medicinelcsh:Sports medicineSedentary timePhysical activitybusiness.industryRehabilitationfood and beverages030229 sport sciencesmedicine.diseaseSedentary timePeer reviewClinical trialShort questionnaire030220 oncology & carcinogenesisPhysical therapylcsh:RC1200-1245businessResearch Article
researchProduct